Morphogenetic variability of faradiol monoesters in marigold Calendula officinalis L.

被引:25
作者
Zitterl-Eglseer, K
Reznicek, G
Jurenitsch, J
Novak, J
Zitterl, W
Franz, C
机构
[1] Univ Vet Med, Inst Appl Bot, A-1210 Vienna, Austria
[2] Univ Vienna, Inst Pharmacognosy, Pharmaziezentrum, A-1090 Vienna, Austria
[3] Univ Hosp Vienna, Dept Psychiat, A-1090 Vienna, Austria
关键词
reversed-phase HPLC; faradiol; faradiol esters; triterpendiol esters; marigold; Calendula officinalis; morphogenetic variability;
D O I
10.1002/pca.582
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The main compounds of lipophilic extracts of flower heads of marigold (Calendula officinalis L.) are triterpendiol esters, mainly faradiol laurate, faradiol myristate and faradiol palmitate. These faradiol-3-O-monoesters have been quantified for the first time by means of reversed phase HPLC with internal standardisation in different parts of C. officinalis plants, namely ray florets, disk florets, involucral bracts, receptacles, leaves and seeds. The amounts of the esters were highest in ray florets, approximately 10 times lower in disk florets than in the ray florets, and approximately 10 times lower in involucral bracts than in the disk florets. In the leaves only traces of the esters could be detected, and in the receptacles no esters could be detected at all. Quantification in the seed was not possible using this method because of interfering fatty compounds. Concerning the faradiol esters, the dried ray and disk florets only should be preferred as primary products for remedies as demanded in the recently published supplement of the Pharmacopoeia Europaea (1999). Breeding work should focus on varieties with a greater number of ray florets in order to improve the quality of herbal medicinal products derived from marigold. Copyright (C) 2001 John Wiley & Sons, Ltd.
引用
收藏
页码:199 / 201
页数:3
相关论文
共 13 条
[1]  
*DAB, 1997, DTSCH AP VERL STUTTG
[2]  
DELLALOGGIA R, 1994, PLANTA MED, V60, P516, DOI 10.1055/s-2006-959562
[3]  
ESCOP (European Scientific Cooperative on Phytotherapy), 1996, MON MED US PLANT DRU
[4]  
HEILMANN J, 1998, 46 ANN C SOC MED PLA, P102
[5]  
ISAAC O, 1994, Z PHYTOTHER, V16, P357
[6]  
*NACHTR RING CAL, 1999, PHARM EUR, P1015
[7]   Genotype x environment interaction in Calendula officinalis L. [J].
Novak, J ;
Zitterl-Eglseer, K ;
Franz, C .
WOCMAP-2: SECOND WORLD CONGRESS ON MEDICINAL AND AROMATIC PLANTS FOR HUMAN WELFARE, PROCEEDINGS: AGRICULTURAL PRODUCTION POST-HARVEST TECHNIQUES BIOTECHNOLOGY, 1999, (502) :67-70
[8]  
SCHEFFER JJC, 1979, PHARM WEEKBLAD, V114, P1149
[9]  
*SCI COMM NAT PHAR, 1992, PHARM FRANC, V10
[10]  
TOSHIHIRO A, 1996, PHYTOCHEMISTRY, V43, P1255